Reports Q4 revenue C$81,655 vs. C$58,273 last year. "I am excited to announce that we delivered another record year in 2022, with revenues of over $290,000, an increase of 21% over last year and record adjusted EBITDA of over $54,000, an increase of 42% over last year. This growth was generated by the full year effect of Exelon and the continued performance of our recent launches, including Lenvima, Halaven and Rembre in Colombia. While delivering on record results, we have completed the transfer of the commercial activities to Knight for Exelon and Akynzeo in our key markets. We continued to advance our pipeline with the regulatory submission of tafasitamab in Brazil, Colombia and Argentina as well as two branded generic products in Chile and Colombia. In addition, to the in-licensing of Akynzeo, we have expanded our pipeline portfolio in our key Latin America markets with fostamatinib and three branded generic products," said Samira Sakhia, CEO.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KHTRF:
